Maintenance Therapy in Multiple Myeloma

Clinical Advances in Hematology & Oncology February 2014, Volume 12, Issue 2 Maintenance Therapy in Multiple Myeloma Shaji Kumar, MD, Professor, Division of Hematology, Mayo Clinic, Rochester, Minnesota H&O How […]

Reassessing Imaging Surveillance in Diffuse Large B-Cell Lymphoma

Clinical Advances in Hematology & Oncology January 2014, Volume 12, Issue 1 Brian K. Link, MD Professor University of Iowa College of Medicine Iowa City, Iowa H&O […]

Watching and Waiting in Mantle Cell Lymphoma

Clinical Advances in Hematology & Oncology December 2013, Volume 11, Issue 12 Peter Martin, MD, The Charles, Lillian and Betty Neuwirth Clinical Scholar in Oncology, Assistant Professor of Medicine, Division […]

Multiple Myeloma: Treatment Updates

Clinical Advances in Hematology & Oncology November 2013, Volume 11, Issue 11 Multiple Myeloma: Treatment Updates James R. Berenson, MD President and CEO James R. Berenson, MD, Inc. […]

Predicting Treatment Outcomes in Older Patients With Acute Myelogenous Leukemia

Clinical Advances in Hematology & Oncology October 2013, Volume 11, Issue 10 Heidi D. Klepin, MD, MS Associate Professor Internal Medicine Section on Hematology […]

Quizartinib in Acute Myeloid Leukemia

Clinical Advances in Hematology & Oncology September 2013, Volume 11, Issue 9 Mark Levis, MD, PhD Director Adult Leukemia Program Associate Professor Oncology, Medicine, and […]

Who Benefits From Surveillance Imaging in Lymphoma?

Clinical Advances in Hematology & Oncology August 2013, Volume 11, Issue 8 James O. Armitage, MD The Joe Shapiro Professor of Medicine, University of Nebraska Medical […]

Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma

Clinical Advances in Hematology & Oncology July 2013, Volume 11, Issue 7 Marc Chamberlain, MD University of Washington, Department of Neurology and Neurological Surgery, Division of Neuro-Oncology, Seattle […]

B-Cell Receptor Inhibitors in Chronic Lymphocytic Leukemia

Clinical Advances in Hematology & Oncology June 2013, Volume 11, Issue 6 Jennifer R. Brown, MD, PhD Director, Chronic Lymphocytic Leukemia Center, Assistant Professor of Medicine, Harvard […]

Update in the Management of Mantle Cell Lymphoma

Clinical Advances in Hematology & Oncology May 2013, Volume 11, Issue 5 Andre Goy, MD, MS Chairman, Executive Director, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, […]

Update on Waldenström’s Macroglobulinemia

Clinical Advances in Hematology & Oncology April 2013, Volume 11, Issue 4 Irene M. Ghobrial, MD Associate Professor, Harvard Medical School, Active Medical Staff, Myeloma Program, Dana-Farber Cancer Institute, Boston, Massachusetts […]

Radiation in Early-Stage Hodgkin Lymphoma

Clinical Advances in Hematology & Oncology March 2013, Volume 11, Issue 3 Ralph M. Meyer, MD, FRCP(C) Edith and Carla Eisenhauer Chair in Clinical Cancer […]

Understanding and Utilizing New Molecular Genetics in MDS

Clinical Advances in Hematology & Oncology February 2013, Volume 11, Issue 2 Maria E. Figueroa, MD Assistant Professor, Department of Pathology, University of Michigan, Ann Arbor, Michigan H&O How […]

Utilizing New Biology to Guide Treatment Directions in Myeloma

Clinical Advances in Hematology & Oncology January 2013, Volume 11, Issue 1 Gareth J. Morgan, MD, PhD Professor of Haematology, Department of Haemato-Oncology, The Institute for Cancer […]

Continued Therapeutic Response Monitoring in Optimal Responders With CML

Clinical Advances in Hematology & Oncology December 2012, Volume 10, Issue 12 H&O What components are involved in molecular monitoring? SB Molecular monitoring in chronic myelogenous […]

Bosutinib in the Treatment of Chronic Myelogenous Leukemia

Clinical Advances in Hematology & Oncology November 2012, Volume 10, Issue 11 H&O What is bosutinib (Bosulif, Pfizer), and what is its mechanism of action? JC […]

Updates in the Treatment of Multiple Myeloma

James R. Berenson, MD President and CEO James R. Berenson, MD, Inc. Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Chief Executive Officer Oncotherapeutics […]

Carfilzomib in Multiple Myeloma

Ravi Vij, MD Associate Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant and Leukemia Division of Medical Oncology St. Louis, Missouri […]

Is Rituximab Maintenance Still Standard of Care in Indolent Non-Hodgkin Lymphoma?

John P. Leonard, MD Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research, Weill Cornell Medical College Vice Chairman for […]

H&O Literature Review: Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients […]